NCT06573593 Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
| NCT ID | NCT06573593 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Alopecia Areata |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-07-29 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-07-29 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
Eligibility Criteria
Inclusion Criteria: * Patients with alopecia areata between 2 to 18 years old * Patients diagnosed with alopecia areata according to AA guideline * AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months Exclusion Criteria: * Patients had previously received hair implants * Other alopecia * Other diseases may induce alopecia including psoriasis, lichen planus, et al. * Unable to estimate SALT score at baseline or at follow-up * Patients are participating in other clinical trials
Contact & Investigator
Xianjie Wu, Ph.D
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Frequently Asked Questions
Who can join the NCT06573593 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 80 Years, studying Alopecia Areata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06573593 currently recruiting?
Yes, NCT06573593 is actively recruiting participants. Contact the research team at dairu@zju.edu.cn for enrollment information.
Where is the NCT06573593 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06573593 clinical trial?
NCT06573593 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Xianjie Wu, Ph.D at Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 150 participants.